Loading...
EXAI logo

Exscientia plcInforme acción NasdaqGM:EXAI

Capitalización bursátil US$633.5m
Precio de las acciones
n/a
US$5.51
n/adescuento intrínseco
1Y-21.9%
7D3.2%
Valor de la cartera
​
Ver

Exscientia plc

Informe acción NasdaqGM:EXAI

Capitalización de mercado: US$633.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Exscientia (EXAI) Resumen de Acciones

Exscientia plc, una empresa de tecnología farmacéutica impulsada por la inteligencia artificial (IA), se dedica a diseñar y desarrollar medicamentos diferenciados para enfermedades con grandes necesidades no cubiertas por los pacientes. Saber más

Análisis fundamental de EXAI
Puntuación del snowflake
Valoración0/6
Crecimiento futuro2/6
Rendimiento pasado0/6
Salud financiera5/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 39.78%

Análisis de riesgos

Los beneficios han disminuido un 41.2% al año en los últimos 5 años

Los accionistas han sido diluidos en el último año


EXAI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
Pharmaceuticals & Biotech opportunity
GANX logo
Gain Therapeutics
Fair Value from
US$7.674.9% infravalorado descuento intrínseco

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.

Read full narrative
Read narrative

Competidores de Exscientia plc

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Exscientia
Precios históricos de las acciones
Precio actual de la acciónUS$4.84
Máximo en las últimas 52 semanasUS$7.91
Mínimo de 52 semanasUS$3.80
Beta0.84
Cambio en 1 mes-0.62%
Variación en 3 meses-19.33%
Cambio de 1 año-21.94%
Variación en 3 años-75.60%
Variación en 5 añosn/a
Variación desde la OPV-82.14%

Noticias y actualizaciones recientes

Recent updates

Seeking Alpha • Aug 08

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Summary Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered value for shareholders since their big-money IPOs, with share prices down by >75%. Both companies have proprietary drugs in their pipeline and programs in which they partner with Big Pharma companies to accelerate drug development. AI hype aside, this is a surprisingly underperforming sector of the stock market, with these types of companies struggling to develop strong pipelines or attract Pharma partners despite a high cash burn. As such, this deal's main strength is creating a larger company that can be more dominant within the industry. With that said, there are potentially valuable accretive data readouts later this year and early next for Recursion's rare disease candidates. Read the full article on Seeking Alpha
Artículo de análisis • Jul 17

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 10

Exscientia: Too Much Pessimism

Summary Exscientia is using AI to improve drug discovery and address the low returns on investments in the pharmaceutical industry. While preclinical data generally looks promising, it is too early to know the overall impact of AI on drug discovery. While there is significant risk, Exscientia's low enterprise value and relatively integrated approach to AI-enabled drug discovery potentially provide an opportunity. Read the full article on Seeking Alpha
Seeking Alpha • May 22

Exscientia: Drug Discovery Platform Attracting Partners And Cash

Summary Exscientia plc's stock has underperformed the biotechnology and IT sectors, despite owning a tech platform attracting big pharma. The company uses AI to accelerate drug development and reduce time to market, potentially improving success rates. The partnerships with major pharmaceutical companies are generating cash inflows and the potential for future royalties. The company differentiates itself using its tech platform, which also uses LLMs (large language models) and Generative (Gen) AI. It is trading at about half its February 2023 peak as the AI hype has deflated but remains vulnerable to interest rate-related risks if the Federal Reserve adopts a hawkish tone. Read the full article on Seeking Alpha
Seeking Alpha • Feb 26

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Summary Exscientia's stock has been stagnant, with a 22% drop after the termination of its CEO due to inappropriate conduct. The company's pipeline efforts include CDK7 inhibitor GTAEXS617 and LSD1 inhibitor EXS74539, with clinical trials starting this year. Exscientia has entered into a collaboration with Sanofi, which could potentially bring in $45 million upfront and $300 million in milestones and royalties. Signals from the market, including shifts among institutional backers and a modest short interest, point to a guarded optimism, indicating potential hurdles in keeping up the momentum. In light of the amalgamation of breakthrough technology, solid financial health, yet mixed market sentiments, and recent executive upheaval, my recommendation shifts to "hold." Read the full article on Seeking Alpha
Artículo de análisis • Jan 11

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Nov 12

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Exscientia plc ( NASDAQ:EXAI ) just released its latest third-quarter results and things are looking bullish. Revenue...
Artículo de análisis • Aug 31

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Celebrations may be in order for Exscientia plc ( NASDAQ:EXAI ) shareholders, with the analysts delivering a...
Artículo de análisis • Aug 25

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Artículo de análisis • Jul 21

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia plc ( NASDAQ:EXAI ) shareholders will have a reason to smile today, with the analysts making substantial...
Artículo de análisis • Apr 22

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Dec 30

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Artículo de análisis • Aug 31

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Today is shaping up negative for Exscientia plc ( NASDAQ:EXAI ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 15

Exscientia: Using AI To Power Drug Development

Today, we take our first look at Exscientia, a unique developmental concern using artificial intelligence or AI to help identify promising drug compounds. Its platform has drawn numerous collaboration deals from the likes of Sanofi and Bristol-Myers Squibb. An investment analysis follows in the paragraphs below. It's not treason if you win. ― Lisa Shearin, Bewitched & Betrayed Today, we put Exscientia (EXAI) in the spotlight for the first time. The developmental biotech concern has a fairly unique method of drug discovery and is headquartered across the pond. The shares came public less than a year ago but are not in 'Busted IPO' territory. What lies ahead for Exscientia? An analysis follows below. Seeking Alpha Company Overview Exscientia is located in Oxford in the United Kingdom. The company is focused on developing small molecule drug candidates. Exscientia's AI developmental platform enables it to design candidate drug molecules, as well as to provide patients with drug therapies. The firms provides end-to-end solution of AI and technologies for target identification, drug candidate design, translational models, and patient selection. The stock currently trades under $13.00 a share and sport a market capitalization just under $1.6 billion. June Company Presentation The company is bringing together a team of industry scientists and technologists which are looking to streamline the drug discovery process by extensively using AI to design and develop better molecules. June Company Overview The company has numerous collaboration partners including Bristol-Myers Squibb Company (BMY), the Bill & Melinda Gates Foundation, and Sanofi (SNY), which came on board this year. June Company Presentation In fact, the new partnership with Sanofi is the biggest news around Exscientia so far in 2022. This agreement provides for the development of up to 15 novel small molecule candidates across oncology and immunology in early January. June Company Presentation The deal provided a $100 million upfront payment to Exscientia which it recorded in April. The company can also earn up to $5.2 billion in additional milestone payments as well sales royalties in the high-single-digits to mid-teens. The agreement also provides an option for clinical co-investment by Exscientia to increase the royalty rate up to 21% on net sales of co-funded products. As can be seen below, this is one of many collaboration deals the company has in place. June Company Presentation Analyst Commentary & Balance Sheet Despite a market cap north of one and a half billion dollars, the company gets little intention from Wall Street. Most likely because of an overseas domicile. On June 13th, Morgan Stanley maintained its Equal Weight rating on the stock and lowered its price target a buck a share to $20. A month prior, Goldman Sachs had reissued its Buy rating and $20 price target on EXAI. That is the only analyst ratings I can find on the stock so far in 2022. June Company Overview Just over two percent of the stock's outstanding float is currently held short. The company ended the second quarter with nearly $720 million in cash and marketable securities after posting a GAAP net loss of -£0.41 a share in the quarter. The company only burned through a bit over $10 million in cash to fund all operations during the last quarter. Verdict The current analyst consensus has the company losing 90 cents a share on $69 million in revenue in FY2022. In FY2023, losses are expected to increase to nearly $1.50 a shares as revenues fall. It should be noted, that few firms have projections on Exscientia's and there is a very wide range to earnings and revenue estimates. Given that all revenues in coming year will come from either developmental milestones within existing collaboration deals or upfront payments from new collaboration agreements, one can't blame analyst firms for having a very difficult time modeling future revenue streams. June Company Presentation The company has made some good progress in showing that its AI enabled platform can more effectively identify promising early stage drug candidates. This is a key reason it has garnered an impressive list of collaboration partners.
Artículo de análisis • May 29

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Rentabilidad de los accionistas

EXAIUS BiotechsMercado US
7D3.2%3.7%3.2%
1Y-21.9%41.9%31.0%

Rentabilidad vs. Industria: Los resultados de EXAI fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 41.9% el año pasado.

Rentabilidad vs. Mercado: EXAI obtuvo unos resultados inferiores a los del mercado US, que fueron del 31% el año pasado.

Volatilidad de los precios

Is EXAI's price volatile compared to industry and market?
EXAI volatility
EXAI Average Weekly Movement8.5%
Biotechs Industry Average Movement10.6%
Market Average Movement7.1%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Precio estable de las acciones: EXAI no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de EXAI (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2012483Dave Hallettwww.exscientia.ai

Exscientia plc, una empresa de tecnología farmacéutica impulsada por la inteligencia artificial (IA), se dedica a diseñar y desarrollar medicamentos diferenciados para enfermedades con grandes necesidades no cubiertas por los pacientes. El principal producto candidato de la empresa es GTAEXS617, un inhibidor de CDK7, que se encuentra actualmente en un ensayo de fase 1/2 para gestionar las posibles toxicidades asociadas a CDK7, así como optimizar la farmacocinética para maximizar la eficacia en el objetivo. También participa en el desarrollo de EXS4318, un inhibidor de PKC-teta, en fase 1 de ensayo clínico para indicaciones inflamatorias e inmunológicas; EXS74539, un inhibidor de LSD1, en estudios preclínicos para SCLC, AML y posibles indicaciones adicionales; EXS73565, un inhibidor de MALT1, en estudios preclínicos para múltiples indicaciones hematológicas; y DSP-0038, actualmente en estudios de fase 1.

Resumen de fundamentos de Exscientia plc

¿Cómo se comparan los beneficios e ingresos de Exscientia con su capitalización de mercado?
Estadísticas fundamentales de EXAI
Capitalización bursátilUS$633.50m
Beneficios(TTM)-US$188.33m
Ingresos (TTM)US$21.36m
29.7x
Ratio precio-ventas (PS)
-3.4x
Ratio precio-beneficio (PE)

¿Está EXAI sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de EXAI
IngresosUK£17.07m
Coste de los ingresosUK£28.63m
Beneficio bruto-UK£11.56m
Otros gastosUK£138.95m
Beneficios-UK£150.51m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-1.15
Margen bruto-67.74%
Margen de beneficio neto-881.79%
Ratio deuda/patrimonio0.1%

¿Cómo se ha desempeñado EXAI a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2024/11/22 07:01
Precio de las acciones al final del día2024/11/19 00:00
Beneficios2024/09/30
Ingresos anuales2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Exscientia plc está cubierta por 3 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Alec StranahanBofA Global Research
Hiroshi ShibutaniGoldman Sachs
Brendan SmithTD Cowen